MedKoo Biosciences

About us  |  Services  |  Products  |  News  |  Careers  |  Contact us

 

 

 


 

Back to products

 

 Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer agents in preclinical trials

Anticancer molecular libraries

 


Other drug agents

Drug intermediates

Bio-reagents and biochemicals

 

 

 

 

 

 

 

 

MedKoo product information:

  

  ARN-509

  

Description of ARN-509: ARN-509, also known as JNJ-56021927,  is an androgen receptor antagonist with potential antineoplastic activity. ARN-509 binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes. This ultimately inhibits the expression of genes that regulate prostate cancer cell proliferation and may lead to an inhibition of cell growth in AR-expressing tumor cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

  

ARN-509, being develop by Aragon Pharmaceuticals,  is currently in a Phase I clinical trial being conducted at Memorial Sloan-Kettering Cancer Center (New York). The open-label, dose-escalation study will determine the safety and tolerability in patients with castration-resistant prostate cancer. 

  

Current developer:    Aragon Pharmaceuticals

  

MedKoo Cat#:  204420

Name:  ARN-509

CAS#:  956104-40-8

Synonym:   ARN-509; ARN 509; ARN509; JNJ-56021927; JNJ56021927; JNJ 56021927

IUPAC/Chemical name: 

4-(7-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl)-2-fluoro-N-methylbenzamide

Chemical structure

Theoretical analysis

MedKoo Cat#:  204420
Name:  ARN-509
CAS#:  956104-40-8

Chemical Formula: C21H15F4N5O2S

Exact Mass: 477.08826

Molecular Weight: 477.43

Elemental Analysis: C, 52.83; H, 3.17; F, 15.92; N, 14.67; O, 6.70; S, 6.72

  

Availability and price:

ARN-509 (99%) is in stock. Price reduced on 12/09/2013. Same day ship out. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee:  $30.00 (USA); $45.00 (Canada); $70.00 (international)

10mg / $150.00

25mg / $250.00

50mg / $350.00

100mg / $550.00

200mg / $850.00

500mg / $1,650.00

1.0g / $2,650.00

2.0g / ask price

5.0g /  ask price

Bulk available at low prices

 ($%^SM@#$ CHEM#$)

Please also see price of Enzalutamide (MDV3100).

  

Technical data

Product data sheet

View product data sheet

Appearance:

white to off-white solid powder

Purity:

>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

View current batch of CoA

QC data:

View NMR, View HPLC, View MS

Safety Data Sheet (MSDS):

View Material Safety Data Sheet (MSDS)

Shipping condition:

Shipped under ambient temperature as non-hazardous chemical.  This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage condition:

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:

Soluble in DMSO, not in water

Shelf life:

>2 years if stored properly

Note: The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

 

Protocols from literature

Drug formulation:

This drug may be formulated in DMSO

Stock solution storage:

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

In vitro protocol:

 

In vivo protocol:

 

 

 

 

 

Information about this agent

The chemical structure of ARN-509 is very similar structure to  that of Enzalutamide (MDV3100) with two minor modifications: (a) two methyl groups in the 5-member ring of MDV3100 is linked by a CH2 group in ARN-509; (b) the carbon atom in the benzene ring of MDV3100 is replaced by a nitrogen atom in ARN-509. ARN-509 is considered as a Me-Too drug of Enzalutamide (MDV3100). ARN-509 was claimed to be more active than Enzalutamide (MDV3100).

   

 

  

ARN-509 is a novel 2nd Generation anti-androgen that is targeted to treat castration resistant prostate cancers where 1st generation anti-androgens fail.  ARN-509 is unique in its action in that it inhibits both AR nuclear translocation and AR binding to androgen response elements in DNA. Importantly, and in contrast to the first-generation anti-androgen bicalutamide, it exhibits no agonist activity in prostate cancer cells that over-express AR. ARN-509 is easily synthesized, and its oral bioavailability and long half-life allow for once-daily oral dosing. In addition, its excellent preclinical safety profile makes it well suited as either a mono- or a combination therapy across the entire spectrum of prostate cancer disease states. (source: http://www.aragonpharm.com/programs/arn509.htm).

  

ARN-509 is  a competitive AR inhibitor, which is fully antagonistic to AR overexpression, a common and important feature of CRPC. ARN-509 was optimized for inhibition of AR transcriptional activity and prostate cancer cell proliferation, pharmacokinetics and in vivo efficacy. In contrast to bicalutamide, ARN-509 lacked significant agonist activity in preclinical models of CRPC. Moreover, ARN-509 lacked inducing activity for AR nuclear localization or DNA binding. In a clinically valid murine xenograft model of human CRPC, ARN-509 showed greater efficacy than MDV3100. Maximal therapeutic response in this model was achieved at 30 mg/kg/day of ARN-509, whereas the same response required 100 mg/kg/day of MDV3100 and higher steady-state plasma concentrations. Thus, ARN-509 exhibits characteristics predicting a higher therapeutic index with a greater potential to reach maximally efficacious doses in man than current AR antagonists. Our findings offer preclinical proof of principle for ARN-509 as a promising therapeutic in both castration-sensitive and castration-resistant forms of prostate cancer. (source: Cancer Res. 2012 Jan 20. [Epub ahead of print])

 

References

1: Clegg NJ, Wongvipat J, Tran C, Ouk S, Dilhas A, Joseph J, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher  HI, Smith-Jones PM, Klang M, Smith ND, de Stanchina E, Wu N, Ouerfelli O, Rix P, Heyman R, Jung ME, Sawyers CL, Hager JH. ARN-509: a novel anti-androgen for prostate cancer treatment. Cancer Res. 2012 Mar 15;72(6):1494-1503. Epub 2012 Jan 20.PubMed  PMID: 22266222.

  

2. Preparation of spiro thiohydantoin compounds as androgen receptor modulators By Smith, Nicholas D.; Bonnefous, Celine; Julien, Jackaline D. From PCT Int. Appl. (2011), WO 2011103202 A2 20110825.

3. Synthesis of thiohydantoins. By Ouerfelli, Ouathek; Dilhas, Anna; Yang, Guangbin; Zhao, Hong. From PCT Int. Appl. (2008), WO 2008119015 A2 20081002

4. Preparation of hydantoins as androgen receptor modulators for the treatment of prostate cancer and other androgen receptor-associated diseases. By Jung, Michael E.; Sawyers, Charles L.; Ouk, Samedy; Tran, Chris; Wongvipat, John. From PCT Int. Appl. (2007), WO 2007126765 A2 20071108.


 

 

Contact MedKoo:

Email: sales@medkoo.com

 

(Keyword; CAS#; MedKoo Cat#)

 

 

 

 

 

 

 

About us  |  Services  |  Products  |  News  |  Careers  |  Contact us

MedKoo Biosciences. All Rights Reserved